Cost of adverse events of bevacizumab plus Interferon-alfa2a compared with Sunitinib for first-line treatment of metastatic renal cell carcinoma;Costo de los eventos adversos de bevacizumab más interferón-alfa2a, en comparación con sunitinib en el tratamiento de primera línea de cáncer de células renales metastásico

Gaceta Mexicana de Oncologia

Volumn 9, Issue 6, 2010, Pages 255-265

  Carlos Rivera, Fernando ^a   Ramiŕez Gámez, Jocelyn ^a   Aguirre Granados, Araceli ^a  

^a R A C Salud Consultores SA de CV   (Mexico)

Author keywords

Adverse drug events; Bevacizumab; Cost analysis; Mexico; Renal cell carcinoma; Sunitinib

Indexed keywords

EID: 84891805570     PISSN: 16659201     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Ochoa F. Actualización del tratamiento en cáncer renal metastásico: un Consenso Mexicano. GAMO 2007;6(Supl. 1):2-10.
2. Corgna E, Betti M, Gatta G, Roila F, De Mulder PH. Renal cancer. Crit Rev Oncol Hematol 2007;64:247-262. (Pubitemid 350026780)
3. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7:245-257.
4. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006;176(6 Pt 1):2353-2358. (Pubitemid 44665976)
5. Rodríguez VH, Serrano E, Maldonado E. Factores pronósticos en cáncer renal localizado y localmente avanzado. Actas Urol Esp 2008;32:320-324.
6. Lang K, Danchenko N, Gondek K, Schwartz B, Thompson D. The burden of illness associated with renal cell carcinoma in the United States. Urol Oncol 2007;25:368-375. (Pubitemid 47362759)
7. Kirchner H, Strumberg D, Bahl A, Overkamp F. Patient-based strategy for systemic treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2010;10:585-596.
8. Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs 2007;67:1257-1264. (Pubitemid 46879093)
9. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park) 2002;16(11 Suppl 13):4-10.
10. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-296. (Pubitemid 34032623)
11. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;(1):CD001425.
12. Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 2006;24:5584-5592. (Pubitemid 46631339)
13. Escudier B, Cosaert J, Jethwa S. Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics 2008;2:517-530.
14. Frampton JE, Keating GM. Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma. BioDrugs 2008;22:113-120. (Pubitemid 351414752)
15. Escudier B. Sunitinib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther 2010;10:305-317.
16. Summers J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2010;15:104-111.
17. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007;12:107-113. (Pubitemid 46143508)
18. European Medicines Agency. EPARs for authorised medicinal products for human use. Avastin: European Public Assessment Report (Revision 15). [Consultado en 2010, julio 27] Disponible en http://www.ema.europa.eu/
19. European Medicines Agency. EPARs for authorised medicinal products for human use. Sutent: European Public Assessment Report (Revision 11). [Consultado en 2010, julio 27] Disponible en http://www.ema.europa.eu/
20. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-2111. (Pubitemid 350296300)
21. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-5428.
22. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. (Pubitemid 46089672)
23. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Clin Oncol 2009;27(22):3584-3590.
24. Coppin C, Le L, Porzsolt F, Wilt T. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2008;(2):CD006017.
25. Porta C, Szczylik C. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev 2009;35:297-307.
26. Mickisch G, Gore M, Escudier B, et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010;102:80-86.
27. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008;13:1084-1096.
28. Cella D. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev 2009;35:733-737.
29. Portal de transparencia del Instituto Mexicano del Seguro Social. [Consultado en 2009, agosto 11-14] Disponible en: http://transparencia.imss.gob. mx/trnsp/ncompro.aspx?c=1
30. Sistema Electrónico de Contrataciones Gubernamentales. [Consultado en 2009, agosto 17-19] Disponible en http://www.compranet.gob.mx/
31. Instituto Mexicano del Seguro Social. Costos Unitarios de Atención Médica. Diario Oficial de la Federación. Viernes 6 de marzo de 2009.
32. Secretaría de Hacienda y Crédito Público. Tabulador de Cuotas de Recuperación 2009. Hospital General "Dr. Manuel Gea González". [Consultado en 2009, agosto 21] Disponible en http://www.hospitalgea.salud.gob.mx/descargas/Tab-cuotas-recup-2009.pdf
33. Morgan-Villela G, Nambo-Lucio MJ, Reynoso-Noverón N. Análisis económico del uso profiláctico de factores estimulantes de colonias para prevenir eventos de neutropenia febril en pacientes que reciben quimioterapia mieloablativa. GAMO 2009;8:26-32.
34. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford, UK: Oxford University Press; 2006; p. 86-92.
35. Schmidinger M, Zielinski CC. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy. Cancer Treat Rev 2009;35:289-296.
36. Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 2009;9:34.
37. Thompson Coon JS, Liu Z, Hoyle M, et al. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 2009;101:238-243.
38. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008;19:1470-1476.
39. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic /pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337. (Pubitemid 36109749)
40. Houk H, Bello C, Michaelson M, et al. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/ pharmacodynamic (PKPD) approach. J Clin Oncol 2007;25(Suppl.):241s. Abstract 5027
41. La Vine DB, Coleman TA, Davis CH, et al. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am J Clin Oncol 2010;33:217-220.
42. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-930.
43. Puente J, Calderero V, García-Muro X, et al. Coste del manejo de los acontecimientos adversos en el tratamiento del carcinoma de células renales metastásico en España. Comparación de bevacizumab + interferon alfa-2a versus sunitinib. Póster presentado en el XII Congreso Nacional SEOM 2009; octubre 21-23; Barcelona, España. Póster P-97. [Consultado en 2010; febrero 27] Disponible en: http://www.postersessiononline. com/312191188-es/congresos/12seom/aula/poster-29122.pdf
44. Mickisch GH, Escudier B, Gore M, et al. Costs of managing side effects using first-line bevacizumab plus lower-dose interferon-α2a in patients with metastatic renal cell carcinoma in Germany, France, and UK. Póster presentado en el Simposio de Cánceres Genitourinarios 2009; febrero 26-28; Orlando, Fl. Abstract 312. [Consultado en 2010, enero 24] Disponible en http://www.asco.org
45. Liou SY, Stephens JM, Carpiuc KT, et al. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig 2007;27:381-396. (Pubitemid 46873100)